PROgnostic Signature in stage II colon cancer (CC) patients enrolled in the phase III clinical trial TOSCA: PROSIT study

被引：0
|
作者：
Puccini, A. [1 ,2 ]
Ferrando, L. [3 ]
Mazzarella, L. [4 ]
Frige, G. [5 ]
Pessino, A. [6 ]
Pastorino, A. [7 ]
Martelli, V. [8 ]
Garuti, A. [2 ]
Ballestrero, A. [2 ]
Torri, V. [9 ]
Labianca, R. [10 ]
Fassan, M. [11 ]
Lonardi, S. [12 ]
Zoppoli, G. [13 ,14 ]
Sobrero, A. [15 ]
机构：
[1] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Rozzano, Italy
[2] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Rozzano, Italy
[3] IRCCS Osped Policlin San Martino, Dept Internal Med, Genoa, Italy
[4] IEO Ist Europeo Oncol IRCCS, New Drug Dev, Expt Oncol, Milan, Italy
[5] IEO Ist Europeo Oncol, Expt Oncol, Milan, Italy
[6] IRCCS Osped Policlin San Martino, Hematooncol Dept, Genoa, Italy
[7] IRCCS Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy
[8] IRCCS Osped Policlin San Martino, Dipartimento Oncol Med 1, Genoa, Italy
[9] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy
[10] ASST Papa Giovanni XXIII, Prov Dept Oncol, Bergamo, Italy
[11] Azienda Univ Osped Padova, Padua, Italy
[12] IOV Ist Oncol Veneto IRCCS, Dept Oncol, Padua, Italy
[13] Univ Genoa, Dept Internal Med, Genoa, Italy
[14] Osped Policlin San Martino IRCCS DiMI, Genoa, Italy
[15] IRCCS Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
25P
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [31] A circRNA signature predicts postoperative recurrence in stage II/III colon cancer
    Ju, Huai-Qiang
    Zhao, Qi
    Wang, Feng
    Lan, Ping
    Wang, Zixian
    Zuo, Zhi-Xiang
    Wu, Qi-Nian
    Fan, Xin-Juan
    Mo, Hai-Yu
    Chen, Li
    Li, Ting
    Ren, Chao
    Wan, Xiang-Bo
    Chen, Gong
    Li, Yu-Hong
    Jia, Wei-Hua
    Xu, Rui-Hua
    EMBO MOLECULAR MEDICINE, 2019, 11 (10)
  • [32] Prognostic factors for patients with stage II colon cancer: results of a prospective study
    Zhang, Chenghai
    Di, Jiabo
    Jiang, Beihai
    Cui, Ming
    Wang, Zaozao
    Xing, Jiadi
    Yang, Hong
    Yao, Zhendan
    Zhang, Nan
    Su, Xiangqian
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2016, 31 (01) : 123 - 129
  • [33] Prognostic factors for patients with stage II colon cancer: results of a prospective study
    Chenghai Zhang
    Jiabo Di
    Beihai Jiang
    Ming Cui
    Zaozao Wang
    Jiadi Xing
    Hong Yang
    Zhendan Yao
    Nan Zhang
    Xiangqian Su
    International Journal of Colorectal Disease, 2016, 31 : 123 - 129
  • [34] A CIRCRNA SIGNATURE PREDICTS POSTOPERATIVE RECURRENCE IN STAGE II/III COLON CANCER
    Ju, Huai-Qiang
    Zhao, Qi
    Wang, Feng
    Lan, Ping
    Wang, Zixian
    Xu, Rui-Hua
    GUT, 2019, 68 : A30 - A30
  • [35] Adjuvant treatment and outcomes in patients with stage III colon cancer (CC) who do not fit clinical trial eligibility criteria (CTEC)
    Javaheri, Khodadad Rasool
    Kennecke, Hagen F.
    Renouf, Daniel John
    Lim, Howard John
    Hsu, Tina
    Speers, Caroline
    Goktepe, Ozge
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [36] A novel prognostic prediction tool for postoperative recurrence in patients with stage II/III colon cancer
    Ma, Jian
    Yang, Burton B.
    CANCER COMMUNICATIONS, 2019, 39 (01)
  • [37] CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
    Dalerba, Piero
    Sahoo, Debashis
    Paik, Soonmyung
    Guo, Xiangqian
    Yothers, Greg
    Song, Nan
    Wilcox-Fogel, Nate
    Forgo, Erna
    Rajendran, Pradeep S.
    Miranda, Stephen P.
    Hisamori, Shigeo
    Hutchison, Jacqueline
    Kalisky, Tomer
    Qian, Dalong
    Wolmark, Norman
    Fisher, George A.
    van de Rijn, Matt
    Clarke, Michael F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (03): : 211 - 222
  • [38] Prognostic Significance of Tumor Deposits in Patients With Stage III Colon Cancer: A Nomogram Study
    Zheng, Peilin
    Chen, Qiaoxing
    Li, Jiake
    Jin, Canguang
    Kang, Lina
    Chen, Donghan
    JOURNAL OF SURGICAL RESEARCH, 2020, 245 : 475 - 482
  • [39] The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.
    Salazar, Ramon
    de Waard, Jan Willem
    Glimelius, Bengt
    Marshall, John
    Klaase, Joost
    Van der Hoeven, Jacobus
    Capdevila, Jaume
    Bibeau, Frederic
    Stork-Sloots, Lisette
    Rosenberg, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [40] The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.
    Salazar, R.
    Rosenberg, R.
    Holzik, M. Lutke
    Marshall, J.
    Van der Hoeven, J. J. M.
    Glimelius, B.
    Bibeau, F.
    Stork-Sloots, L.
    Bender, R. A.
    Capdevila, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345